|
|
|
|
|
|||||||
|
Session 89
Poster Session
HBV Co-Infection 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 672-M. | Incidence of Acute Hepatitis B (HBV) Infection in HIV-Infected Persons and the Impact of HB Vaccination and Lamivudine S. E. Kellerman*, D. L. Hanson, and A. McNaghten CDC, Atlanta, GA
| ||
| 673-M. | Hepatitis B Virus and HIV Co-Infection: Development of Lamivudine Resistance L. Cooley1, A. Bartholomeusz1, A. Ayres1, S. Mack1, S. Locarnini1, A. Mijch2, S. Crowe3, and J. Sassadeusz*4 1Victorian Infectious Diseases Reference Lab; 2Alfred Hosp.; 3Macfarlane Burnet Ctr. for Med. Res.; and 4Royal Melbourne Hosp., Australia
| ||
| 674-M. | Antiviral Efficacy and Rate of Development of Resistance in Patients Treated 1 Year for Chronic HBV Infection with FTC A. Sykes*, C. Wakeford, F. Rousseau, A. Rigney, and E. Mondou Triangle Pharmaceuticals, Durham, NC
| ||
| 675-M. | Tenofovir Disoproxil Fumarate Suppresses Lamivudine Resistant HBV Replication in Patients Co-Infected with HIV/HBV M. Bochet1, R. Tubiana1, Y. Benhamou*1, V. Thibault1, L. Suffisseau1, C. Brosgart2, J. Rooney2, M. Sullivan2, T. Poynard1, F. Bricaire1, and C. Katlama1 1GH Pitié-Salpêtrière, Paris, France and 2 Gilead Sci. Inc., Foster City, CA
|
